Invea Therapeutics

Biotechnology ResearchConnecticut, United States11-50 Employees

Invea Therapeutics is a biotechnology company focused on developing small molecule oral therapeutics for immune-mediated inflammatory diseases. Its aim is to deliver safe, effective therapies that modulate inflammation, protect tissue integrity, and support long-term disease remission, addressing conditions such as atopic dermatitis and chronic urticaria where current options may be limited or ineffective for some patients. The company combines artificial intelligence and machine learning with its scientific expertise to investigate the mechanisms and pathways that drive inflammation, supporting its drug discovery and development efforts. Its lead candidate, INVA8001, is planned to advance into Phase 2b, while INVA8003 is in early preclinical development, reflecting a pipeline approach to tackling IMIDs. Invea Therapeutics is based in Guilford, Connecticut, and operates with a focus on translating mechanistic insights into targeted oral therapies. A recent board appointment in December 2024 indicates ongoing leadership development to support its clinical progression.

Sign up for free to view info

Email Format Employee directory